Proteomics Analysis of Distinct Portal Vein Tumor Thrombi in Hepatocellular Carcinoma Patients

Guo, Wei-Xing; Xue, Jie; Shi, Jie; Li, Nan; Shao, Yuan; Yu, Xiuchong; Shen, Feng; Wu, Mengchao; Liu, Shanrong; Cheng, Shuqun

doi:10.1021/pr100412w

Cited by 18 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…XAGE-1b was shown to be a risk factor affecting PVTT, TNM staging and the 1-year recurrence. PVTT in HCC patients is a well-known major complication that is correlated with a poor prognosis (22). The patients with PVTT or higher TNM stages (II~IV) were found to be more likely to have increased XAGE-1b mRNA levels.…”

Section: Discussionmentioning

confidence: 93%

XAGE-1b expression is associated with the diagnosis and early recurrence of hepatocellular carcinoma

Pan

Tang

Hou

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. XAGE-1b is a 470 bp transcript of the XAGE-1 gene, which belongs to the cancer-testis antigens that exhibit a restricted pattern of expression in normal tissues. Recently, the expression of XAGE-1b has been shown to be frequent in patients with hepatocellular carcinoma (HCC). However, the underlying mechanism is not fully understood. To investigate the role of XAGE-1b in HCC diagnosis and postoperative evaluation, the expression level of XAGE-1b was first examined in the tissue and peripheral blood of HCC patients and controls by using quantitative polymerase chain reaction. Subsequently, the associations between XAGE-1b and the clinical variables were assessed using χ 2 or Kaplan-Meier tests. The data showed that HCC tissues had increased XAGE-1b expression when compared to paired non-tumorous tissues. The blood samples from the HCC patients showed upregulated XAGE-1b mRNA, as compared to non-HCC patients. The patients with portal vein tumor thrombus or higher tumor-node metastasis stages (II~IV) were more likely to have increased levels of XAGE-1b mRNA. Furthermore, the 1-year recurrence rate of the patients with a high level of XAGE-1b mRNA was significantly greater compared to the patients with a low level. All these findings indicate that XAGE-1b is associated with the aggressive biological behavior of HCC cells and it may be a potential biomarker for HCC diagnosis and prognosis.

show abstract

Section: Discussionmentioning

confidence: 93%

XAGE-1b expression is associated with the diagnosis and early recurrence of hepatocellular carcinoma

Pan

Tang

Hou

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…As the majority of PVTT emerges around the primary tumor (aPVTT), the traditional belief is that PVTT develops following the direct invasion of a liver tumor, resulting in a hepatic artery-portal vein fistula and portal vein countercurrent. However, we detected distinct PVTT (dPVTT), a unique type of PVTT distant from the liver tumor nodule 16 . Comparative proteomics showed that dPVTT possessed molecular signatures different from those of liver tumors, implying that the mechanism of PVTT formation is far more complicated than previously thought.…”

Section: Mechanisms Of Pvtt Formationmentioning

confidence: 85%

Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma

Sun

Shi

et al. 2016

Cancer Biology & Medicine

View full text Add to dashboard Cite

The effect of portal vein tumor thrombus (PVTT) on the prognosis of patients with hepatocellular carcinoma has become clear over the past several decades. However, identifying the mechanisms and performing the diagnosis and treatment of PVTT remain challenging. Therefore, this study aimed to summarize the progress in these areas. A computerized literature search in Medline and EMBASE was performed with the following combinations of search terms: “hepatocellular carcinoma” AND “portal vein tumor thrombus.” Although several signal transduction or molecular pathways related to PVTT have been identified, the exact mechanisms of PVTT are still largely unknown. Many biomarkers have been reported to detect microvascular invasion, but none have proved to be clinically useful because of their low accuracy rates. Sorafenib is the only recommended therapeutic strategy in Western countries. However, more treatment options are recommended in Eastern countries, including surgery, radiotherapy (RT), transhepatic arterial chemoembolization (TACE), transarterial radioembolization (TARE), and sorafenib. Therefore, we established a staging system based on the extent of portal vein invasion. Our staging system effectively predicts the long-term survival of PVTT patients. Currently, several clinical trials had shown that surgery is effective and safe in some PVTT patients. RT, TARE, and TACE can also be performed safely in patients with good liver function. However, only a few comparative clinical trials had compared the effectiveness of these treatments. Therefore, more randomized controlled trials examining the extent of PVTT should be conducted in the future.

show abstract

“…It is likely that Annexin A5 has a very short unphosphorylated N-terminus compared with other Annexins, contributing to a series of functions, such as cell proliferation and invasion (6,10), signal transduction (11,12), and anticoagulation (13). Previous studies have reported that Annexin A5 promoted tumorigenesis and progression in a variety of cancers, including hepatocarcinoma, colorectal cancer and breast cancer (14,15). However, the possible relationship between Annexin A5 and RCC is not clear.…”

Section: Introductionmentioning

confidence: 99%

High Annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma

Tang

Qin

Han

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

Annexin A5 has been found to act as an oncogenic protein in a variety of cancers. However, its specific biological role and mechanism in renal cell cancer (RCC) remains unknown. Quantitative Real-time PCR and western blotting were used to evaluate the mRNA and protein expression level of Annexin A5 in human RCC cell lines and tissues. Immunohistochemistry was adopted to measure the Annexin A5 expression in 123 cases of RCC tissues. Survival analysis was performed to explore the association between Annexin A5 expression and the prognosis of RCC. The effect of Annexin A5 on RCC growth and metastasis was studied in vitro and in vivo. Annexin A5 was frequently highly expressed in both human RCC cells and tissues. High Annexin A5 expression was associated with higher clinical stage and histological grade. In addition, Annexin A5 might be used as a predictive factor for the prognosis of RCC. Further research suggested that upregulated Annexin A5 in RCC cells could significantly promote tumor cell proliferation, migration and invasion in vitro. Subcutaneous xenograft tumor model displayed that knockdown of Annexin A5 could impede tumorigenesis in vivo. Moreover, mechanism study exhibited that Annexin A5 could activate PI3K/Akt/mTOR signaling pathway, promote epithelial-mesenchymal transition (EMT) and the expression of MMP2 and MMP9. Annexin A5 may be a potential prognostic biomarker in RCC and promotes proliferation, migration and invasion of RCC cells via activating PI3K/Akt/mTOR signaling pathway and regulating EMT process and MMP expression.

show abstract

Proteomics Analysis of Distinct Portal Vein Tumor Thrombi in Hepatocellular Carcinoma Patients

Cited by 18 publications

References 34 publications

XAGE-1b expression is associated with the diagnosis and early recurrence of hepatocellular carcinoma

XAGE-1b expression is associated with the diagnosis and early recurrence of hepatocellular carcinoma

Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma

High Annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma

Contact Info

Product

Resources

About